Redhill Biopharma (NASDAQ:RDHL) is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.
RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health. Its development pipeline includes Bekinda® (RHB-102), an ondansetron formulation for the treatment of acute gastroenteritis and irritable bowel syndrome with diarrhea, which has completed pivotal trials and is under regulatory review. In addition, RedHill is evaluating RHB-204, a liposomal formulation targeting pulmonary nontuberculous mycobacterial infections, and RHB-107, a serine protease inhibitor being explored in oncology indications.
With research and development activities spanning North America, Europe and Israel, RedHill maintains offices in Tel Aviv and a U.S. subsidiary in Raleigh, North Carolina. The company leverages contract research organizations and clinical sites across multiple geographies to advance its candidates through Phase III studies. RedHill’s business development efforts have yielded strategic licensing and distribution partnerships to support commercial launches and broaden market access for its products.
RedHill is led by Chief Executive Officer Amir Reichman, who brings experience in biopharmaceutical development and commercialization to the company’s operations. Under his leadership, the management team and board of directors are committed to executing on late-stage clinical programs, securing regulatory approvals and building commercial infrastructure to support patient access to novel therapies.
